ESMO TAT (Targeted Anticancer Therapies), known as “The Home of Phase I in Oncology”, is the leading congress focusing on promising new anticancer targets and agents, with a particular emphasis on those in early phase clinical development.

This congress will be dedicated to improving the conduct of early anti-cancer clinical trials, bringing together those who are developing the most promising new cancer drugs and unveiling exciting new data.

Stakeholders from academia and industry will discuss with clinicians, researchers, and regulators the global dissemination of knowledge and clinical research expertise in the field of innovative cancer therapeutics, to the benefit of cancer patients worldwide.